Presented By: Sami Ullah, PhD
Speaker Biography: Dr. Sami Ullah is working as a scientist in the cancer biology group at one of Europe’s largest cell line repositories, the DSMZ (German collection of cell cultures and microorganisms). He has a Ph.D. in Biotechnology where he focused on developing in vitro and in vivo models for diseases mechanism studies and drug delivery. Later, he focused on the development of cell culture models with the idea to replicate the in vivo conditions in vitro. At DSMZ, he is developing high-throughput 3D cell culture systems for different types of cancers and developing a pipeline to transfer the available cell cultures to serum-free cell culture.
Webinar: Optimising Cell Line Development for Bioprocessing
Webinar Abstract: In the last decades, the upstream processing in biopharma industry has been revolutionized regarding the production of bioactive materials such as monoclonal antibodies, proteins and biotherapeutics. More and more cell lines are produced with an aim to increase the productivity and quality of biologics produced. For instance, the mammalian cell lines have gained extreme importance in production of recombinant proteins for different applications. This is in general because of the fact that mammalian cell lines allow proper protein folding and post-translational modification. Although, the process itself starts with introduction of a “gene of interest” in to the cell line, there are a number of factors which needs to be taken in to account before claiming the cell line for biologics production.
Earn PACE Credits:
1. Make sure you’re a registered member of Labroots (www.labroots.com/)
2. Watch the webinar on KZread or on the Labroots Website (www.labroots.com/webinar/opti...)
3. Click Here to get your PACE credits (Expiration date - 04/06/2024): www.labroots.com/credit/pace-...
Labroots on Social:
Facebook: / labrootsinc
Twitter: / labroots
LinkedIn: / labroots
Instagram: / labrootsinc
Pinterest: / labroots
SnapChat: labroots_inc